Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Data Mining HeData Mining Helps Detect Adverse Drug Reactions

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Print article
A new study suggests that information held in electronic medical records (EMRs) can validate previously reported adverse drug reactions (ADRs) and report new ones.

Researchers at the New Jersey Institute of Technology (NJIT; Newark, USA) examined 12 years of EMR data from Vanderbilt University Medical Center (VUMC; Nashville, TN, USA; www.mc.vanderbilt.edu) and reviewed retrospective medication orders and inpatient laboratory results documented in the EMR to identify ADRs. The researchers then assessed the relative merits of six pharmacovigilance measures used in spontaneous reporting systems: proportional reporting ratio (PRR), reporting OR (ROR), Yule's Q (YULE), the CHI-squared test, Bayesian confidence propagation neural networks (BCPNN), and a gamma Poisson shrinker (GPS).

The researchers then systematically evaluated the six methods on two independently constructed reference standard datasets of drug-event pairs. The first was the Yoon et al dataset, containing 470 drug-event pairs (10 drugs and 47 laboratory abnormalities). The second dataset was created using the VUMC EMRs, containing 378 drug-event pairs (9 drugs and 42 laboratory abnormalities). After evaluation, CHI, ROR, PRR, and YULE all had the same F score (62%). When the reference standard of Yoon et al was used, ROR had the best F score of 68%, with 77% precision and 61% recall. The study was published in the May 2013 issue of the Journal of American Medical Informatics Association.

“Medication safety requires that each drug be monitored throughout its market life as early detection of adverse drug reactions can lead to alerts that prevent patient harm,” said lead author computer scientist Mei Liu, PhD. “EMRs have created an unprecedented resource for observational studies since they contain not only detailed patient information, but also large amounts of longitudinal clinical data.”

Pharmacovigilance is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of ADRs, which are defined as any response to a drug, which is noxious and unintended, including lack of efficacy, which occurs at doses normally used for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. ADRs are one of the major causes for failure in drug development, and severe ADRs that go undetected until the postmarketing phase of a drug often lead to patient morbidity, as exemplified by numerous drug withdrawals.

Related Links:

New Jersey Institute of Technology



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.